Postes actifs de Jonathan Hahn
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Tuteur SA | Directeur/Membre du Conseil | 01/01/2013 | - |
| President | 01/01/2013 | - | |
| Corporate Officer/Principal | 01/01/2013 | - | |
| Tuteur SACIFIA | Directeur/Membre du Conseil | 01/01/2013 | - |
| President | 01/01/2013 | - |
Historique de carrière de Jonathan Hahn
Anciens postes connus de Jonathan Hahn
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | - | - |
| KAMADA LTD. | Directeur/Membre du Conseil | 25/03/2010 | - |
Formation de Jonathan Hahn
| University of San Andres | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Statistiques
Internationale
| Argentine | 4 |
| Etats-Unis | 3 |
| Israël | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| President | 2 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KAMADA LTD. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Tuteur SA | |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
| Tuteur SACIFIA |
- Bourse
- Insiders
- Jonathan Hahn
- Expérience
